User talk:Kammerhofer Sylvia/My sandbox: Difference between revisions

From Bioblast
No edit summary
No edit summary
 
(76 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{TRANSMIT page name}}
{{Template:OROBOROS header page name}}
:::: <big><big>TRANSlating the role of MITochondria in Tumorigenesis</big></big>


:::: <big><big>TRANSMIT - TRANSlating the role of MITochondria in Tumorigenesis</big></big>
[[Image:Horizon2020_logo_jpg.jpg‎|right|150px|Horizon 2020]]


[[Image:Logo MitoFit-OROBOROS.jpg|right|300px|MitoFit]]
 
[[Image:European_commission_logo.png‎|right|150px|European commission]]
'''Cancer is not only a genetic, but also a metabolic disease'''
'''Cancer is not only a genetic, but also a metabolic disease'''
:::: The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer.  
:::: The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer.  
Line 10: Line 13:
== Objectives ==
== Objectives ==


:::: TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.
:::: '''TRANSMIT aims to dissect the metabolic remodeling in human cancers''', placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies.  
 
:::: Further, '''TRANSMIT fosters the communication''' of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients.  
 
:::: By creating the critical mass of scientific excellence, '''TRANSMIT will allow to transfer the current knowledge''' into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.
 


:::: '''TRANSMIT key methodologies and key objectives'''
::::The proposal envisions three scientific WPs. For each WP, several ESRs are recruited as indicated below the WP title. Scientific WPs share the key methodologies indicated within the four sectors of the romboid in light grey. The implementation of key methodologies in pairs allows the achievement of the key objectives indicated by the dark grey arrowheads.


=== Coordinator ===
:::: [[Image:TRANSMIT key methodologies and key objectives.jpg|750px|Key methodologies and key objectives]]


:::: Alma Mater Studiorum – Università di Bologna - Italy
== Coordinator ==
 
:::: [http://www.unibo.it/en/ Alma Mater Studiorum – Università di Bologna] - IT
:::: Submitted by Anna-Maria Porcelli and Serena Paterlini (University of Bologna)
:::: Submitted by Anna-Maria Porcelli and Serena Paterlini (University of Bologna)




=== Partners/List of Participants ===
== List of Participants ==
 


::::  
::::TRANSMIT is a multi-partner project that intends to mobilize the critical mass of expertise, by linking partners from 7 different countries, among which world-leading basic science and clinical centers of excellence, 4 SMEs as full partners, as well as non-profit foundations with a long-lasting history of dealing with the societal consequences of cancer in patients and their families.




::::* [http://www.unibo.it/en/ Alma Mater Studiorum – Università di Bologna] - IT
::::* [http://www.uclouvain.be/index.html/ Universite Catholique de Louvain] - BE
::::* [http://wiki.oroboros.at/index.php/OROBOROS_INSTRUMENTS/ OROBOROS INSTRUMENTS GmbH] - AT
::::* [https://www.uni-giessen.de/welcome/ Justus Liebig Universität Giessen] - DE
::::* [https://www.salk.at/ Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft]  - AT
::::* [http://ki.se/start/ Karolinska Institutet]  - SE
::::* [https://www.cam.ac.uk/ The Chancellor, Masters and Scholars of the University of Cambridge] - UK
::::* [http://www.adera.fr/ Association pour le développement de l'enseignement et des recherches aupres des universities et des enterprises d’aquitaine] - FR
::::* [http://www.biocrates.com/ Biocrates Life Sciences AG] - AT
::::* [http://www.avanticell.com/ AvantiCell Science Ltd] - UK


[[Image:MitoCom Tyrol.jpg|left|80px|link=MitoCom O2k-Fluorometer|MitoCom]]
:::: The logo of ''MitoCom Tyrol'' (now transformed to MitoFit) is based on ''MiPArt'' by [http://www.mipart.at/?Odra-Noel Odra Noel]. ''Further details:'' »[[MitoCom O2k-Fluorometer]].


[[Image:University_of_Bologna_logo.png‎|60px|University of Bologna]]
[[Image:Universite_Catholique_de_Louvain_logo.jpg‎‎|80px|Universite Catholique de Louvain]]
[[Image:Logo OROBOROS INSTRUMENTS.jpg|80px|link=http://wiki.oroboros.at/index.php/OROBOROS_INSTRUMENTS OROBOROS]]
[[Image:Justus_Liebig_Universität_Giessen_logo.png‎‎‎|120px|Justus Liebig Universität Giessen]]
[[Image:SALK_logo.png‎‎‎‎|140px|Salzburger Landeskliniken]]
[[Image:Karolinska_Institutet_logo.jpg‎‎‎‎‎|140px|Karolinska Institutet]]
[[Image:Adera_logo.png‎|110px|Adera]]
[[Image:Biocrates_logo.png‎‎|130px|Biocrates Life Sciences AG]]
[[Image:AvantiCell_Science_logo.png‎‎‎|130px|AvantiCell Science Ltd]]
[[Image:University_of_Cambridge_logo.png‎‎‎‎‎‎|220px|University of Cambridge]]


[[Image:MitoCom-Kuehtai 3453-web.jpg|430px|link=MitoCom O2k-Fluorometer|MitoCom Tyrol]]


== Partner organisations ==


::::* [http://www.fondazioneveronesi.it/ Fondazione Umberto Veronesi] - IT
::::* [http://www.innovasrl.net/ Innova SRL] - IT
::::* [http://www.ceub.it/ CEUB Il Centro Residenziale Universitario di Bertinoro (Ce.U.B.)] - IT
::::* [http://www.dynamoacademy.org/ Dynamo Academy srl Impresa Sociale] – IT




[[Image:MitoFit.jpg|left|60px|link=http://www.mitofit.org/index.php/K-Regio MitoFit|K-Regio MitoFit]]
[[Image:Fondazione_Umberto_Veronesi.png‎‎|110px|Fondazione Umberto Veronesi]]
'''See also'''
[[Image:Innova_srl.jpg‎ |150px|Innova srl]]
:::* '''[[K-Regio MitoFit]]''' is the next step following the K-Regio project ''MitoCom'' (mitochondrial competence; [[MitoCom_O2k-Fluorometer|O2k-Fluorometer]]), extending our world-wide technological leadership in mitochondrial respirometry with the development of a quality control system, MitoFit-Knowledge Management Platform and applications in preventive medicine (K-Regio project MitoFit).
[[Image:Centro_Residenziale_Universitario.png‎ |90px|Centro Residenziale Universitario die Bertinoro]]
:::* Health tourism: http://www.tt.com/wirtschaft/7750785-91/mehr-gesundheit-f%C3%BCr-tirol-urlauber.csp
[[Image:Dynamo_Academy.png‎|90px|Dynamo Academy]]
:::* [http://www.uibk.ac.at/ipoint/dossiers/forschung_im_fokus/983677.html Sport science in focus]

Latest revision as of 10:52, 14 October 2016

                



User talk:Kammerhofer Sylvia/My sandbox

TRANSMIT - TRANSlating the role of MITochondria in Tumorigenesis
Horizon 2020

European commission

Cancer is not only a genetic, but also a metabolic disease

The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer.


Objectives

TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies.
Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients.
By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.


TRANSMIT key methodologies and key objectives
The proposal envisions three scientific WPs. For each WP, several ESRs are recruited as indicated below the WP title. Scientific WPs share the key methodologies indicated within the four sectors of the romboid in light grey. The implementation of key methodologies in pairs allows the achievement of the key objectives indicated by the dark grey arrowheads.
Key methodologies and key objectives

Coordinator

Alma Mater Studiorum – Università di Bologna - IT
Submitted by Anna-Maria Porcelli and Serena Paterlini (University of Bologna)


List of Participants

TRANSMIT is a multi-partner project that intends to mobilize the critical mass of expertise, by linking partners from 7 different countries, among which world-leading basic science and clinical centers of excellence, 4 SMEs as full partners, as well as non-profit foundations with a long-lasting history of dealing with the societal consequences of cancer in patients and their families.



University of Bologna Universite Catholique de Louvain link=http://wiki.oroboros.at/index.php/OROBOROS_INSTRUMENTS OROBOROS Justus Liebig Universität Giessen Salzburger Landeskliniken Karolinska Institutet Adera Biocrates Life Sciences AG AvantiCell Science Ltd University of Cambridge


Partner organisations


Fondazione Umberto Veronesi Innova srl Centro Residenziale Universitario die Bertinoro Dynamo Academy

Cookies help us deliver our services. By using our services, you agree to our use of cookies.